1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Addresses Concerns Over Switching Multinational Studies To Clinical Trials Regulation

 
• By Vibha Sharma

EU regulators are to speed up their evaluation of applications to transition ongoing multinational studies to the CTR.

Business, Technology, Internet and network concept. Business man working on the tablet of the future, select on the virtual display: Clinical trial
Sponsors must consider several factors before transitioning ongoing studies to the Clinical Trials Regulation • Source: Shutterstock/ Den Rise

With approximately 18 months remaining for studies authorized under the erstwhile EU Clinical Trials Directive (CTD) to switch to the Clinical Trials Regulation (CTR), member states have agreed on a new expedited, one-week evaluation procedure to support the transition of multinational clinical trials meeting certain requirements.

The expedited procedure is explained in a “

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.